Quest Diagnostics Inc vs Synopsys, Inc. — how do they compare? Quest Diagnostics Inc trades at $237.5 (market cap $26.21B), while Synopsys, Inc. trades at $410.55 (market cap $78.68B). The key difference: Synopsys, Inc. is far larger — about 3× Quest Diagnostics Inc's market cap, and Quest Diagnostics Inc pays a 1.45% dividend while Synopsys, Inc. pays none. Which is the better fit depends on your goals.
| DGX | SNPS | |
|---|---|---|
Market Cap | $26.21B | $78.68B |
Sector | Health | Technology |
52-Week High | $238.50 | $625.80 |
52-Week Low | $173.49 | $372.33 |
Enterprise Value | $31.97B | $87.04B |
Dividend Yield | 1.45% | — |
Trailing returns across standard periods
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →